



VLP Based Coronavirus Vaccines

Guest Editors:

Prof. Dr. Martin Bachmann

Department of Immunology,
University of Bern, 3012 Bern,
Switzerland

Dr. Mona O. Mohsen

Department of Biomedical
Research, University of Bern,
3012 Bern, Switzerland

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Dear Colleagues,

The COVID-19 pandemic has paralyzed the world, however with the advent of registered vaccines, a silver lining is on the horizon. These novel vaccines are, however, based on novel techniques, which do not yet have the full experience package of classical vaccines. On the other hand, the use of virus-like particles (VLPs) is one such classical vaccine approach. In this Special Issue of *Vaccines*, we would like to highlight the various efforts made and techniques used in the development of virus-like particle (VLP)-based COVID-19 vaccines. We would like to cover all aspects of vaccine development, from vaccine design to vaccine production, as well as preclinical and clinical efficacy. This Special Issue will highlight the power of the classical VLP-based approach and underline the importance that such avenues are still pursued to back up the vaccines currently undergoing registration.

Prof. Dr. Martin Bachmann

Dr. Mona Mohsen

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com